Nice to see your own thread, Dabum! I've enjoyed your posts here and the RIG board; you're teaching this ole FA dog some new tricks. <vbg>
I followed you a while back into MLNM and was happy to see this news today. Have you updated your analysis recently?
CAMBRIDGE, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Researchers at Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) and the Brigham and Women's Hospital today presented results from seven studies in rheumatoid arthritis (RA) that could pave the way for the development of more effective, less toxic therapies that are custom-designed for each patient based on his or her genetic make-up. The research, which was shared during the American College of Rheumatology meeting in San Antonio, Texas, offers new insight into genetic clues to better understand RA risk, underlying disease mechanisms, and response to treatment.
"The research presented at ACR brings Millennium one step closer to fulfilling our goal of delivering personalized medicine for patients with rheumatoid arthritis," said Robert Tepper, M.D., president of research and development, Millennium. "The study findings, based on data from our significant patient registry, could one day help medical professionals predict who will develop RA, how severe their disease may become, which patients will respond best to which treatments, and how aggressively to treat them -- based on each patient's unique genetic makeup."
"These are exciting discoveries that we can now put to use in our development and discovery efforts, such as incorporating newly-identified biomarkers for treatment response into clinical trials designed to identify the right medicine for the right patients," said Ronenn Roubenoff, M.D., M.H.S., senior director, molecular medicine, Millennium. |
